Gingko Max
Gingko Max, licence 80004439: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Jamieson Laboratories Ltd./ Nutricorp International
- NPN or DIN-HM
- 80004439
- Status
- Active licence
- Licence date
- 6 November 2007
- Revision date
- 19 June 2009
- Form
- Caplet
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Ginkgo biloba L.: L'étiquetage des compléments alimentaires qui contiennent la feuille de la plante Ginkgo biloba L. doit comporter un avertissement avec la teneur suivante: "Consultez votre médecin en cas de prise simultanée d'anticoagulants."
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Ginkgo biloba Source : Feuille(s) Extraction ratio : 50:1 Dry plant equivalent : 2000 mg Potency : 24.0 % Flavoglycosides | 40.0 mg | Not calculated |
| Ginkgo biloba Source : Feuille(s) Potency : 6.0 % Terpene lactones | Not specified | Not calculated |
Non-medicinal ingredients
Polysaccharides de soja, cellulose, Acide stéarique végétale, Stéarate de magnésium végétal, Phosphate de dicalcium dihydrate
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 2.0 Caplet | 1.0 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps to enhance cognitive function and memory in older adults. Helps to support peripheral circulation.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80004439
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2009. Photograph the packaging to check whether it has changed.
Has the product changed? Photograph the packaging.